免疫检查点与常见头颈部鳞状细胞癌的临床研究现状  

Clinical research on immune checkpoint and head and neck squamous cell carcinoma

作　　者：于丹[1] 齐欣萌[1] 赵雪[1] 刘岩[1] 薛凯[1] 金春顺[1] 文连姬[1] 

机构地区：[1]吉林大学第二医院耳鼻咽喉头颈外科,长春130041

出　　处：《中华耳鼻咽喉头颈外科杂志》2017年第9期717-720,共4页Chinese Journal of Otorhinolaryngology Head and Neck Surgery

基　　金：国家自然科学基金青年基金（81502348）;国家自然科学基金（81572653）;吉林省科技厅青年基金（20150520042JH）;吉林省自然科学基金（20160101039JC）

摘　　要：近年来,T细胞免疫检查点信号通路因参与了肿瘤免疫逃逸机制而成为了新的研究热点.T细胞免疫检查点及其配体的表达不仅调控着肿瘤的免疫微环境,也和恶性肿瘤的发生、分期及预后密切相关,还有望成为肿瘤复发和转移的生物学监测指标.目前免疫检查点抑制剂在包括头颈部鳞状细胞癌（head and neck squamous cell carcinoma,HNSCC）在内的多种实体肿瘤中开展了大量的临床试验,并展示出良好的治疗前景,已经成为肿瘤免疫治疗的新靶点.本文将针对T细胞免疫检查点相关基因及蛋白在HNSCC免疫微环境中的表达、与临床预后相关性及其抑制剂在HNSCC临床免疫治疗中的应用现状作一综述.T cell immune checkpoint pathways contribute to tumor immune escape.Many studies have shown that immune checkpoint is demonstrably correlated with tumor grade or prognosis in several types of malignancies and immune checkpoint has become a new biological index for tumor detection and prognosis.Immune checkpoint inhibitors have shown promising tumor outcomes in clinical trials for some advanced solid tumors and it will become a new target for cancer immunotherapy.In this review we will explore the correlation between expressions of immune checkpoint-associated genes and proteins in immune microenviroment and prognosis of head and neck squamous cell carcinoma,and specifically will discuss how this pathway can be manipulated with immune therapeutic drugs.

关 键 词：头颈部肿瘤 癌 鳞状细胞 CTLA-4 PDl/PDLl分子 免疫检查点 免疫治疗 

分 类 号：R739.91[医药卫生—肿瘤]